NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio
PRESS RELEASENanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio FORT WORTH, Texas, ...
NanOlogy Unveils Drug Development Program for Rare Pediatric Brainstem Tumor
PRESS RELEASE NanOlogy Unveils Drug Development Program for Rare Pediatric Brainstem Tumor Next Generation Intratumoral Technology Targets Diffuse Intrinsic Pontine Glioma Investigational New Drug ...
Therapeutic Advances in Medical Oncology: Systemic and locoregional therapies for cutaneous metastases from breast cancer: state of art and new frontiers in treatment approach
Journal for ImmunoTherapy of Cancer: Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease April 18, ...
Journal of Thoracic Oncology: Phase 2a Intratumoral Large Surface Area Microparticle Paclitaxel in Stage 3/4 Lung Cancer
Journal for ImmunoTherapy of Cancer: Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease April 1 ...
JDDG: Cutaneous metastases: From epidemiology to therapy
Journal for ImmunoTherapy of Cancer: Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease April 1 ...
NanOlogy Publishes Research Articles on the Immunomodulatory Effects of its Large Surface Area Microparticle Investigational Drugs
NanOlogy Publishes Research Articles on the Immunomodulatory Effects of its Large Surface Area Microparticle Investigational Drugs FORT WORTH (February 14, 2024) — NanOlogy LLC, a clinical-st ...
NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC
NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC Interim response and peripheral immunomodulation data from its Phase 2 clinical trial of IT LSAM-PTX in stage 3/4 lung ca ...
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the IASLC North America Conference on Lung Cancer
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the IASLC North America Conference on Lung Cancer FORT WORTH (November 20, 2023) — NanOlogy LLC, a clinical-stage oncology ...
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting FORT WORTH (October 23, 2023) — NanOlogy LLC, a clinical-stage oncology company, announced to ...
Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer
Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer Research article published in Pancreas ...
NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer
NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer FORT WORTH (September 12, 2023) — NanOlogy LLC, a clinica ...
